Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany discusses the results of the recent Phase III CLL11 trial (NCT01998880). The CLL11 trial compared different chemoimmunotherapy combinations of chlorambucil, rituximab and obinutuzumab in chronic lymphocytic leukaemia (CLL). Dr Eichhorst highlights the promising results, including a significant overall survival benefit with the anti-CD20 monoclonal antibody obinutuzumab. This video was recorded at the at the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden.
CLL11 trial shows improved OS rates in CLL with obinutuzumab
